Clinical trial · Interventional
Assessment of QoL and Outcomes With SBRT for RCC
Assessment of Quality of Life and Outcomes in Patients Treated With Stereotactic Body Radiation Therapy (SBRT) for Primary Renal Cell Carcinoma (RCC) - AQuOS-RCC
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Stereotactic body radiotherapy (SBRT) is an emerging radiotherapy technique that precisely delivers high doses of radiation to tumours. It has been investigated as definitive treatment for an increasing variety of primary tumours including lung, liver, prostate, and now renal cell carcinoma (RCC). The principal aims of this study are to prospectively assess quality of life (QoL) and oncologic outcomes in non-surgical patients who receive SBRT for the treatment of RCC.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Renal Cell Carcinoma | Renal Cell Carcinoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| SBRT | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- SBRT
- description
- RCC patients
- interventionNames
- Radiation: SBRT
Primary outcomes (1)
- measure
- Patient Quality of Life
- timeFrame
- Up to 5 years after treatment
- description
- To evaluate quality of life scores
Secondary outcomes (5)
- measure
- Cost-Effectiveness
- timeFrame
- Up to 5 years after completion of treatment
- description
- To assess health utility scores and correlate with QoL
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients ≥18 years old * Medically inoperable or patient who refuses surgery * Histologic diagnosis of RCC where possible, or radiologic evidence of growth on surveillance * Lesion ≥2.5cm or recurrent lesion following local ablative therapy * Written informed consent * Participants must be able to understand the English-language or with the aid of a translator Exclusion Criteria: * ECOG ≥3 * Prior abdominal radiation
References
Publications (0)
Data not yet available